Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALVOVAR trial in poor-prognosis ovarian cancer after neoadjuvant chemotherapy
NL-OMON60676Phase 3Not yet recruiting
- Sponsor
- Arcagy-Gineco
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and paclitaxel in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoints: Late complete debulking surgery rate after 3 additional randomized chemotherapy cycles and Overall survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON60676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60676.